SCHEMBL886532

SCHEMBL886532

Fc1cccc(F)c1-c1nc(C(Cc2cccnc2N2CCCCC2)c2cccnc2)no1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 13/20 0.36
KCNH2 Q12809 5/20 0.35
LMNA P02545 2/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
USP2 O75604 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.32
TSHR P16473 1/20 0.32
MAPK1 P28482 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
HSD17B10 Q99714 1/20 0.32
GUCY1B2 O75343 1/20 0.32
GUCY1A2 P33402 1/20 0.32
GUCY1A1 Q02108 1/20 0.32
GUCY1B1 Q02153 1/20 0.32
RPS6KB1 P23443 1/20 0.32
SRC P12931 1/20 0.32
ALOX5AP P20292 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2062500 0.91 KCNA5 (0.39) KCNA5KCNH2LMNANPC1RAB9A
SCHEMBL885452 0.89 RPS6KB1 (0.38) KCNA5KCNH2LMNANPC1RAB9A
SCHEMBL885978 0.88 KCNA5 (0.42) KCNA5KCNH2LMNANPC1RAB9A
SCHEMBL885665 0.88 KCNA5 (0.42) KCNA5KCNH2LMNANPC1RAB9A
SCHEMBL886322 0.88 KCNA5 (0.39) KCNA5KCNH2LMNAUSP2ALDH1A1
SCHEMBL885622 0.88 KCNA5 (0.36) KCNA5KCNH2RPS6KB1ALOX5AP
SCHEMBL884813 0.87 KCNA5 (0.43) KCNA5KCNH2LMNANPC1RAB9A
SCHEMBL2062372 0.87 KCNA5 (0.38) KCNA5KCNH2ALDH1A1RPS6KB1ALOX5AP
SCHEMBL884952 0.85 KCNA5 (0.40) KCNA5KCNH2LMNAUSP2ALDH1A1
SCHEMBL2063221 0.85 ALDH1A1 (0.41) KCNA5KCNH2LMNANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 US claimed
EP-1940406-A2 POTASSIUM CHANNEL INHIBITORS Merck and Co., Inc. (US) 2008-07-09 EP claimed
WO-2007050348-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-05-03 WO claimed
US-8148535-B2 Potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2012-04-03 US disclosed
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233897-A1 Potassium Channel Inhibitors KCNJ2, KCNQ2, KCNH2 KCNA5 11/4885KCNH2 3/4885LMNA 815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.